Serabelisib

Modify Date: 2024-01-29 15:42:59

Serabelisib Structure
Serabelisib structure
Common Name Serabelisib
CAS Number 1268454-23-4 Molecular Weight 363.37000
Density 1.6±0.1 g/cm3 Boiling Point N/A
Molecular Formula C19H17N5O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Serabelisib


Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.

 Names

Name [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone
Synonym More Synonyms

 Serabelisib Biological Activity

Description Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.
Related Catalog
Target

p110α:15 nM (IC50)

p110β:4500 nM (IC50)

p110δ:13900 nM (IC50)

p110γ:1900 nM (IC50)

mTOR:1670 nM (IC50)

In Vitro Serabelisib (MLN1117) inhibits Akt phosphorylation and growth in PIK3CA mutant breast cancer cells with IC50s around 2 μM, yet has no effect on cells lacking PTEN. BCR-stimulated B cells treated with 1 μM Serabelisib (MLN1117) displays a significant reduction (up to 50%) in the magnitude of the phosphorylated Akt (p-Akt) signal measured by intracellular flow cytometry. The effect of Serabelisib is dose-dependent[1].
In Vivo Treatment with Serabelisib (MLN1117) at 30 and 60 mg/kg causes little reduction of TNP-specific IgG3. Notably, reduction of TNP-specific IgG3 at higher doses of Serabelisib (MLN1117) (120 mg/kg) is observed, consistent with the partial reduction in cell division in B cells treated with Serabelisib before anti-IgM stimulation. However, 120 mg/kg is above the effective dose of Serabelisib (MLN1117) for tumor growth inhibition (30-60 mg/kg)[1].
Cell Assay A total of 5000 SK-OV-3 and U87MG cell lines/well in low serum media (0.2% FBS) are seeded in triplicate wells of a 96-well flat bottom culture plate for 18 h to adhere. Media is aspirated and inhibitors in 0.2% FBS media are added to each well at the indicated concentrations. After 48 h, cell viability is determined using the MTS assay (Cell Titer 96 Aqueous One solution cell proliferation assay kit) with absorbance (490 nm) measured in a microplate spectrophotometer[1].
Animal Admin Mice[1] Wild-type 8-week-old Balb/cJ mice are used for all experiments. Serabelisib and GDC-0941 are given by oral gavage using a sterile disposable 20-guage 1.5′ feeding needle. IC87114 is delivered via intraperitoneal injection. For the non-immunization experiment, 2 mice per group (Vehicle, GDC-0941, and Serabelisib (MLN1117)) are given the indicated drugs for 9 days before sacrificing on day 10. For the immunization experiment, 4 mice per group are used to perform two independent studies comparing GDC-0941 or IC87114 to Serabelisib (MLN1117). In all cases, the vehicle group receive both vehicles used to formulate the two different drugs. Mice are treated with the drugs throughout day -1 to day 13. On day 0, all mice are immunized with NP-OVA precipitated in alum. Drug treatment is stopped on day 13 and mice are sacrificed for collection of serum and spleens.
References

[1]. So L, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem. 2013 Feb 22;288(8):5718-31.

 Chemical & Physical Properties

Density 1.6±0.1 g/cm3
Molecular Formula C19H17N5O3
Molecular Weight 363.37000
Exact Mass 363.13300
PSA 99.62000
LogP 1.40
Index of Refraction 1.768
Storage condition -20℃

 Synonyms

UNII-43J9Q56T3W
[6-(2-amino-4,6,7-trideuterio-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone
INK 1117
INK-1117
Methanone, [6-(2-amino-5-benzoxazolyl)imidazo[1,2-a]pyridin-3-yl]-4-morpholinyl-
[6-(2-Amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl](4-morpholinyl)methanone
serabelisib
MLN 1117
TAK-117
MLN1117
Top Suppliers:I want be here




Get all suppliers and price by the below link:

Serabelisib suppliers


Price: $119/10mM*1mLinDMSO

Reference only. check more Serabelisib price